Biktarvy and Phenergan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) and Phenergan (promethazine hydrochloride). Common drug interactions include anxiety among females and emotional distress among males.

The phase IV clinical study analyzes what interactions people have when they take Biktarvy and Phenergan. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Biktarvy?

Biktarvy has active ingredients of bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 19,543 Biktarvy users. Check the latest studies of Biktarvy.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.



On Aug, 13, 2026

18 people who take Biktarvy and Phenergan together, and have interactions are studied.

Biktarvy and Phenergan drug interactions.

What are the common drug interactions of Biktarvy and Phenergan, by gender? *:

female:

  1. Anxiety
  2. Emotional distress
  3. Pain
  4. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  5. Osteoporosis (bones weak and more likely to break)
  6. Back pain
  7. Bone density decreased
  8. Bradykinesia (decreased bodily movement. it is associated with basal ganglia diseases)
  9. Depression
  10. Pain in extremity

male:

  1. Emotional distress
  2. Pain
  3. Dysuria (painful or difficult urination)
  4. Fatigue (feeling of tiredness)
  5. Nephrolithiasis (calculi in the kidneys)
  6. Osteonecrosis (death of bone)
  7. Proteinuria (presence of protein in the urine)
  8. Renal disorder (kidney disease)
  9. Arthralgia (joint pain)
  10. Foot fracture

What are the common drug interactions of Biktarvy and Phenergan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Ankle fracture
  3. Anxiety
  4. Bone density decreased
  5. Decreased activity
  6. Emotional distress
  7. Facial bones fracture (bone fracture of face)
  8. Jaw fracture
  9. Osteoporosis (bones weak and more likely to break)
  10. Pain

30-39:

  1. Bone density decreased
  2. Emotional distress
  3. Pain
  4. Anxiety
  5. Arthralgia (joint pain)
  6. Depression
  7. Foot fracture
  8. Hand fracture
  9. Intervertebral disc degeneration (spinal disc degeneration)
  10. Osteonecrosis (death of bone)

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Emotional distress
  4. Pain
  5. Renal impairment (severely reduced kidney function)
  6. Bone density decreased
  7. Chronic kidney disease
  8. Proteinuria (presence of protein in the urine)
  9. Renal disorder (kidney disease)
  10. Tooth loss

50-59:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Emotional distress
  4. Pain
  5. Bradykinesia (decreased bodily movement. it is associated with basal ganglia diseases)
  6. Salivary hypersecretion (excess saliva secretion)
  7. Somnolence (a state of near-sleep, a strong desire for sleep)
  8. Back pain
  9. Bone density decreased
  10. Bone loss

60+:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Pain
  4. Pain in extremity
  5. Pain in jaw
  6. Quality of life decreased
  7. Rib fracture
  8. Spinal fracture (fracture in one of vertebrae)
  9. Arthralgia (joint pain)
  10. Back pain

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 22.22%
  2. High Blood Pressure: 4 people, 22.22%
  3. Hypersensitivity: 3 people, 16.67%
  4. Pain: 3 people, 16.67%
  5. High Blood Cholesterol: 3 people, 16.67%
  6. Rickets (softening of bones): 2 people, 11.11%
  7. Prostatic Disorder: 2 people, 11.11%
  8. Stress And Anxiety: 2 people, 11.11%
  9. Infection: 2 people, 11.11%
  10. Wheezing (a high-pitched whistling sound made while you breath): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Biktarvy and Phenergan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Biktarvy and Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Biktarvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Biktarvy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Phenergan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate and promethazine hydrochloride (the active ingredients of Biktarvy and Phenergan, respectively), and Biktarvy and Phenergan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: